Clinical observation of treatment for menopause induced by perimenopausal uterine leiomyoma with different dose of mifepristone
- VernacularTitle:不同剂量米非司酮治疗围绝经期子宫肌瘤诱导绝经的临床效果观察
- Author:
Zhenqiu PAN
;
Liying FAN
;
Yabei JIN
- Publication Type:Journal Article
- Keywords:
mifepristone;
dose;
perimenopause;
uterine leiomyoma;
induced menopause
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;(12):79-80,83
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the different doses of mifepristone in treatment of menopause induced by perimenopausal uterine leiomyoma , and to explore the clinical application of the effective dose of mifepristone.Methods 141 cases with perimenopausal uterine leiomyoma were divided into group A, group B and group C randomly, 47 cases in each group.Three group of patients were given mifepristone.Group A were treated with dose of 12.5 mg/d, group B was treated with 10.0 mg/d, group C was given with 5.0 mg/d.Three groups of patients continued treatment for three months. Uterine volume and leiomyoma volume were observed after treatment, and recorded status of induced menopausal after six months.Results Three groups with uterine volume and leiomyoma volume post-treatment were significantly less than pre-treatment (P<0.05);induction of menopause success rate of group A was 89.4%, menstruation incidence was 6.4%, vaginal bleeding was 2.1%, which was significantly better than the other two groups ( P<0.05) .Conclusion Different doses of mifepristone orally in treatment of perimenopausal uterine leiomyoma has a significant effect, but with 12.5mg/d induced menopause can effectively enhance the success rate , it could be used as the optimal dose of clinical treatment.
